Dr. Reddy's recalls some lots of heartburn drug in U.S.

Image
Reuters MUMBAI
Last Updated : Mar 13 2014 | 2:48 PM IST

MUMBAI (Reuters) - Generic drugmaker Dr. Reddy's Laboratories Ltd is recalling about 58,656 bottles of the heartburn drug lansoprazole in the United States due to a microbial contamination, the U.S. Food and Drug Administration said.

It was classified as a "Class II" recall which indicates a remote chance of severe adverse consequences or death due to the product flaw.

While product recalls are not uncommon, the FDA announcement comes amid a string of quality problems for Indian drug makers.

In a weekly report, the U.S. regulator also announced it was banning imports from Sun Pharmaceutical Industries Karkhadi manufacturing plant in the western state of Gujarat.

And just last week, the FDA disclosed that products made by Sun Pharma and Ranbaxy Laboratories were being recalled.

Dr. Reddy's voluntary recall of lansoprazole delayed release capsules, a generic version of Swiss drugmaker Novartis' drug Prevacid 24 HR, began on January 3, 2014, the FDA said on its website.

A spokesman for Dr. Reddy's was not immediately available to comment.

(Reporting by Zeba Siddiqui; Editing by Edwina Gibbs)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 13 2014 | 2:35 PM IST

Next Story